Telomir Pharmaceuticals reported on November 12, 2025, that its investigational compound Telomir-1 significantly outperformed the FDA-approved iron chelator Deferoxamine in reducing intracellular iron levels in human cells, showing strong potential for mitigating oxidative stress and related diseases.